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Introduction
Our preliminary results suggested that human metastatic breast cancer cells with restored BRMS1 expression significantly downregulated their TNF-α and HER2 expression. Moreover, based on our recently published microRNA array data, we identified miR-125b as one of the microRNAs increased by BRMS1 expression (1) . MiR-125b is one of the most consistently deregulated miRs in breast cancer and, similar to BRMS1, was shown to be significantly downregulated in HER2+ breast cancers (2) . Consequent analysis of the 3' UTR region of HER2 revealed target sites for miR-125b, while its overexpression in HER2-dependent breast cancer cell lines showed decreased cell mobility and invasiveness (3) (4) . Additionally, mir-125b targets TNF-α directly for post-transcriptional repression (5) , suggesting that this miR is, at least partially, responsible for regulation of HER2 and TNF-α in breast cancer. Therefore, I hypothesize that BRMS1 regulates TNF-α and HER2 expression via its regulation of miR-125b.
Results

PART I.
Before implementing labor-and time-intensive work outlined in the original grant proposal, we first set off to confirm our original preliminary data that served as the basis for our hypothesis. Below is the summary of our findings.
Expression of BRMS1 is inversely correlated with expression of HER2 in human breast cancer biopsy samples
To confirm our previously published results (6), we examined BRMS1 expression in primary tumor biopsies of 24 breast cancer patients with known HER2 status (12 patients clinically diagnosed with HER2+ and 12 patients -with HER2-disease). As shown in Figure 1 and Table  1 , there is a strong inverse correlation (p=0.013) between histologically scored expression of HER2 and BRMS1, supporting our hypothesis that BRMS1 may negatively regulate HER2 expression.
To obtain data shown in Table 1 , semi-quantitative analysis of immunoreactivity was ranked into three groups according to the percentages of positive tumor cells: negative and low positive (-/+, 0-25%), medium positive (++, 26-50%), and high positive (+++, >50%). Immunoreactivity was scored based on a well-established immunoreactivity score system in which immunoreactivity score was generated by incorporating both the percentage of positive tumor cells and the intensity of staining (7). Staining intensity was based on cross-product of the percentages of tumor cells staining at each staining intensities (H score). Immunoreactivity was assigned as described previously based on at least 200 cells counted (8) . Slides were read by a blinded pathologist. Data were analyzed using Pearson Chi-Square test. These experiments were outlined in Task 3.1a (Aim 3, months 24-30). While the sample size we used was small (we originally proposed a 170 patient tissue array, while only 24 patient samples were used), we wanted to confirm that our homemade antibody raised against BRMS1 (developed by Dr. Welch's lab) produced reproducible results, since human tissues are always of a limited supply. In the process of performing these verification studies, we discovered that BRMS1 antibody produces very high background, making it difficult for our staff pathologist to conclusively distinguish positive and negative cases.
MiR-125b decreases HER2 expression level, but has no effect on cell proliferation
We then confirmed that miR-125b targets HER2, reducing its protein level. For these studies, we requested miR-125b construct previously described in (3) and established stable cell lines using parental MDA-231 and MDA-435 breast cancer cells ( Figure 2A ). As expected, in both cell lines expression of miR-125b resulted in lower expression of HER2 ( Figure 2B) . Surprisingly, as shown in Figure 2C we could not reproduce the previously published observation that expression of miR-125b suppresses cell proliferation (4). One possible explanation for this phenomenon is that levels of miR-125b expression obtained in our cells were insufficiently high to inhibit cell proliferation. We stated in our original proposal that we would attempt to identify the molecular interplay between BRMS1, HER2 and miR-125b using two well-characterized metastatic breast cancer cell lines, MDA-231 and MDA-435. However, both of these cell lines are considered "normal" HER2 expressers, i.e. HER2 is not amplified. Therefore, we screened several other metastatic breast cancer cell lines and identified MCF10-CA-d1.α and KPL4 as two cell lines where HER2 protein expression level is elevated (data not shown). Specifically, KPL4 were reported to exhibit a 15-fold HER2 gene amplification (9) , while MCF10-CA-d1.α exhibit HER2 protein level higher than that of MDA-231 or MDA-435 cells.
We then wanted to ensure that in our hands, these two reportedly metastatic (9-10) cell lines would produce metastases in vivo. Hence, we performed two pilot animal studies using these cell lines by injecting them intravenously (MCF10-CA-d1.α) or via intracardiac route (KPL4). As expected, both cell lines were highly metastatic ( Figure 3 ). We are currently in the process of establishing variants of these two cell lines that stably express GFP-Luciferase fusion protein under control of the CMV promoter. Expression of GFP and Luciferase will enable us to better assess systemic disease upon injection of these cells into the animals, as well as better control of the experimental timeline. While our original proposal specified use of mKate2 instead of GFP, our current technical capabilities will preclude us from using a far-red fluorescent protein for in vivo or ex vivo imaging. A. MCF10 CA d1.α cells were injected intravenously and animals monitored for signs of lung metastases, such as dyspnea and wasting. All mice were sacrificed at week 7 post-injection, lungs fixed in Bowen's buffer and number of surface metastatic nodules counted under low magnification dissecting microscope. Data shown are one representative whole lung specimen with white metastatic colonies. Bar graph shows a mean number of nodules counted for all five mice in the study ± SEM. B. KPL4 cells were injected systemically via the left ventricle of the heart. Animals were monitored for signs of bone metastases, such as hind leg paralysis, hunched posture and wasting. All mice were sacrificed at different times upon detection of above symptoms. In total, ¾ animals developed presumed bone lesions, although histologic examination is yet to be completed.
BRMS1 has no significant effect on expression of miR-125b and HER2.
Based on our preliminary data from MDA-435 cells, we expected about 2-3 fold enhancement of miR-125b expression in BRMS1-expressing cells. Furthermore, we expected about 50% reduction in HER2 levels in BRMS1 expressing cells. As shown in Figure 4A , miR-125b levels were enhanced by BRMS1 expression in both MDA-231 and MDA-435 cell lines, although not to the degree expected. Moreover, there is a great variation in miR-125b expression level from one experiment to the next, suggesting that expression of this microRNA may be relatively low in these cells, a possibility further supported by a high (between 32-34) cycle number when this microRNA is detected.
We then assessed level of HER2 expression by qPCR to gain insight into whether miR-125b may regulate HER2 at the level of transcription. As shown in Figure 4B (red bars), there was a much greater decrease in HER2 gene expression in MDA-435 cells as compared to MDA-231 cells. This decrease in HER2 expression also translated into a detectable decrease in HER2 protein level in these cells ( Figure 4C ). Conversely, in MDA-231 cells there was a much lower reduction in HER2 gene expression (blue bars, Figure 4B ) and no detectable change in HER2 protein level ( Figure 4C ) between vector control and BRMS1-expressing cells.
Since it is thought that amplification of HER2 gene and/or elevation of its protein level may affect cell's behavior, we developed MCF10-CA-d1.α and KPL4 cells stably expressing BRMS1. As shown in Figure 4C , both cell lines have low endogenous BRMS1 expression. However, upon stable transfection of BRMS1 driven by CMV promoter (and tagged with Flag epitope at the Nterminus), no detectable change in HER2 protein level was detected.
From this set of experiments we therefore conclude that BRMS1 has only a marginal effect on miR-125b expression and no cell line independent effect on HER2 protein expression in these breast cancer cells. While the work outlined in 2.4 is not a perfect match to the original SOW, additional cell lines were included because they exhibit HER2 gene amplification (KPL4) and high levels of HER2 protein (KPL4 and MCF10-CA-d1.α) and are representative of human HER2+ breast cancer classification, versus MDA-MB-231 and MDA-MB-435 cell lines that exhibit basal HER2 levels. We feel that by including these additional cell lines we enhanced relevance of our studies to the human disease. Moreover, including these additional cell lines were necessitated by our finding that BRMS1 only suppressed HER2 expression in MDA-MB-435, but not in MDA-MB-231, cell line. Consequently, we were able to show that out of four cell lines tested, HER2 expression was only suppressed in MDA-MB-435 cells. This finding lead us to question our original hypothesis that BRMS1 regulates expression of HER2.
PART II.
In the process of characterizing BRMS1-induced behavior that might account for enhanced anoikis and reduced survival during cell circulation in vivo, we observed that BRMS1 expression results in a delayed cell adhesion. To investigate this finding further we performed the following set of experiments and are currently in the process of finalizing data for publication (see Reportable Outcomes, manuscript in preparation).
Summary Review raised a concern that the original Progress Report we submitted outlined results of studies (such as adhesion and MET studies, below) not approved in the SOW. While we agree that these studies were not originally proposed, we feel that they are highly relevant. One of the points discussed in the original application is that BRMS1-expressing cells are less capable of reaching the bone through the circulatory system. Our original hypothesis was that downregulation of HER2 contributed to this "anoikis" phenotype. We further hypothesized that reduced TNF-α expression contributed to reduced growth of BRMS1-expressing cells in the bone. However, seeing that BRMS1 does not significantly affect HER2 or TNF-α expression, we were able to show that BRMS1-expressing cells exhibit retarded adhesion dynamics through delayed cytoskeletal rearrangement and activation of adhesion-associated signaling pathways. Moreover, we made an interesting observation that BRMS1 delays mesenchymal-to-epithelial transition, which may also contribute to BRMS1-associated anoikis.
Expression of BRMS1 delays adhesion of breast cancer cells to matrix.
Vector control and BRMS-expressing MDA-231 and MDA-435 breast cancer cells were plated on plates pre-coated with FBS to simulate conditions encountered by cells during in vivo dissemination. Time-lapse microscopy of live, unlabeled cells was utilized to assess adhesion kinetics. Essentially, we propose that a cell that dissociated from a primary tumor and entered circulation in order to metastasize must undergo a morphologic change from round (in circulation) to eventually fully attached and spread ( Figure 5A ). There are also a number of signaling changes associated with this morphologic transformation, starting with formation of focal adhesions and activation of integrins and culminating in transcriptional activation.
As shown in Figure 5B , BRMS1 expression greatly inhibited adhesion kinetics. Although if left undisturbed BRMS1-expressing cells eventually adhere, adhesion takes a much longer time. 
BRMS1 decreases focal adhesion number and inhibits its associated signaling.
It has been previously shown that adhesion is mediated through assembly of and signaling through focal adhesions at the cell surface (11) . We thus examined whether BRMS1 expression played a role in modulating expression or activity of major players in focal adhesion assembly: integrins, focal adhesion kinase (FAK), talin, or integrin linked kinase (ILK).
One of the first steps in formation of focal adhesions is the activation of integrins. Integrin β1 is the main binding partner for most α subunits. Therefore, examining activation status of this integrin can serve as a read-out for activation of many integrin heterodimers. As shown in Figure  6A , upon plating cell suspension onto FBS-coated plates and allowing cells to attach for 15 minutes, activated β1 integrin localizes to the outer-most plasma membrane (indicated by green spots, arrows). However, in cells stably expressing BRMS1 cell spreading is greatly reduced ( Figure 5B ) and localization of activated β1 integrin to focal adhesions is hampered ( Figure 6A) . The next step in activation of focal adhesions is recruitment FAK and its phosphorylation by Src kinase. As shown in Figure 6B , cells expressing BRMS1 exhibit a dramatic decrease in cell spreading, evidenced by highly condensed cytoplasm and reduced actin cytoskeleton remodeling. Furthermore, localization of phosphorylated FAK (pFAK) to the plasma membrane is also greatly decreased ( Figure 6B, arrows) .
To determine key players in assembly and functionality of focal adhesions affected by BRMS1 expression, we preformed a time course experiment where cells in suspension were allowed to attach to FBS-coated plates for times indicated, then lysed and examined by immunoblotting. As shown in Figure 6C , there is a significant decrease in levels of all components of the focal adhesion signaling complex examined: talin, pFAK, and ILK. Immunoblotting results were quantified and data shown in Figure 6D , 6E.
Overall, from these data we conclude that BRMS1 expression delays cell attachment to matrix by hampering integrin activation with consequent inhibition of focal adhesion signaling. We also show that this phenomenon is independent of type of matrix used (data not shown).
Figure 6. Expression of BRMS1 in inhibits formation of focal adhesion complexes. A.
Vector control and BRMS1-expressing breast cancer cells were plated onto chamber slides precoated with FBS and allowed to adhere for 15 minutes. Fixed cells were immunostained for actin (red) and activated β1 integrin (green). Arrows point to areas staining for activated β1 integrin and localized to the outer-most plasma membrane. Scale bar = 20µm. B. Vector control and BRMS1-expressing cells were plated onto chamber slides pre-coated with FBS and allowed to adhere for 30 minutes. Fixed cells were stained for actin (red) and pFAK (green). Arrows point to focal adhesions, as indicated by green staining. Scale bar = 20µm. C. Vector and BRMS1-expressing cells were plated onto plates pre-coated with FBS and lysed at time points indicated. Cell lysates were assayed by western blotting for levels of focal adhesion markers. Expression of Talin and pFAK from three independent experiments were enumerated using ImageJ and data are shown in D and E. Statistical analysis was performed using T-test. *p<0.05
BRMS1 may play a role in mesenchymal-to-epithelial transition (MET).
It is currently thought that cells that metastasize must change their physical appearance during their journey from primary tumor to a distant site. Specifically, it is believed that mesenchymal cells possess qualities that yield in their escape from the primary tumor, while cells that acquire an epithelial phenotype are better at colonizing secondary sites (12) . This EMT/MET switch manifests itself, in part, through modulation in expression of epithelial (E-cadherin) and mesenchymal (ZEB1, Snail) markers. Because we have previously shown that BRMS1 expressing cells remain as single cells at secondary sites (13) (14) and our current data point to BRMS1-induced inability of cells to properly respond to their microenvironment, we hypothesized that BRMS1 may inhibit MET.
We first examined expression of E-cadherin, ZEB1, and Snail in vector and BRMS1-expressing breast cancer cells grown in normal culture. As shown in Figure 7A , there was little difference in expression of ZEB1 and Snail, while E-cadherin was not detected in these cells (data not shown). These data indicated that under normal conditions, both of these cell lines exhibit mesenchymal characteristics. We then reasoned that our adhesion assay may be useful in assessing forced morphologic change a cell must undergo upon arriving at the secondary site (MET). As shown in Figure 7B , upon plating cell suspension onto FBS-coated plates, expression of ZEB1 and Snail changes. Interestingly, expression of Snail is reduced in BRMS1-expressing cells at an earlier time point (15 minutes) while expression of ZEB1 is reduced after 1 hour post-plating. These data might indicate sequential regulation of these mesenchymal markers. However, data also suggest that BRMS1 may delay MET when cells reach secondary sites, which may also lead to their reduced survival in circulation in vivo. 
Concerns about original collaborations
During the review of the original progress report, a concern was raised regarding our collaboration with investigators at UAB. As you may already know, Dr. Danny Welch had since moved from UAB to the Kansas University Medical Center. We continue our collaboration with Dr. Welch and his former postdoc, Dr. Douglas Hurst, who is currently an Assistant Professor in the Department of Pathology at UAB. However, we could not continue our collaboration with Dr. Andra Frost, a clinical pathologist from UAB, due to Dr. Frost's departmental service restrictions. Consequently, Dr. Weiya Xia, a clinical pathologist in Dr. Hung's lab at MDACC, has been working with us on all human tissue-associated immunohistochemistry. Furthermore, our collaboration with Drs. Zayzafoon and Feng from UAB is also questionable, mainly because our original hypothesis may not be fully correct. However, should we need their expertise, they will be willing to uphold their original agreement of collaboration.
3. Future work 3.1. Because BRMS1 has a pronounced effect on cells' cytoskeleton (both actin and microtubules), we will utilize our newly established cells expressing Flag-tagged BRMS1 to determine whether BRMS1 directly interacts with members of the cytoskeleton. We believe that BRMS1 may have a yet unknown role restricted to cytosole based on two key pieces of evidence: i) BRMS1 is detected in cytosole of most breast cancer tumor biopsies, yet it is presumed role as part of Sin3A complex is restricted to the nucleus and ii) BRMS1 has been shown to interact with HDAC6, a cytosolic protein that regulates stability of microtubules. We will isolate BRMS1-associated proteins by performing immunoprecipitation (i.p.) and subject utilize i.p. products to mass spectrometry to identify proteins that differentially bind to BRMS1 in the nucleus vs. cytosole. If BRMS1 and HDAC6 can interact and/or regulate one another's function, we will also utilize inhibitors specific for HDAC6 to determine whether they could enhance suppression of metastasis in cells with normal BRMS1 expression. 3.2. We recently observed that BRMS1 may have an effect on MET. We will continue to work on identifying a potential molecular mechanism underlying this phenomenon. Specifically, we will try to delineate why Snail is reduced earlier and ZEB1 is reduced later in the process of cell attachment/adhesion and how BRMS1 may regulate them. Presumably, BRMS1 could be involved in regulating the transcription of these two genes through its activity within Sin3A complex. Moreover, we recently observed that BRMS1 is involved in regulation of levels of cytoskeleton-dependent serum response factor (SRF) transcription factor. Many genes that play a role in adhesion, migration, and proliferation are under the control of SRF. Interestingly, one recent article proposed that Snail expression is dependent on presence of sera in the media, raising a question whether BRMS1 regulates Snail through its regulation of SRF. 3.3. To further examine the role of BRMS1 in MET and regulation of adhesion/colonization of secondary sites, we would like to also propose some in vivo studies. We will utilize cells with or without BRMS1 expression that are tagged with eGFP-Luciferase fusion protein.
Following either spontaneous metastases of cells grown in the mammary fat pad or after intravenous injection, we will isolate lungs. Some lungs will be stained for betaglycosidase, a marker of senescence, to determine if BRMS1-expressing cells are unable to colonize secondary sites because they are senescent. Cells from other sets of lungs will be isolated and screened through non-biased approaches (gene array, Chip array to examine epigenomic status of cells) for markers of MET. We may also perform this experiment in a time-course setting to determine whether time-specific regulation of Snail and ZEB1 are relevant to behavior of cells in vivo. 
